Summary

Colorado has recently become the first state to explicitly safeguard neural data privacy, enacting a law on Wednesday, April 17th, 2024. Essentially, this legislation acknowledges that data generated by the nervous system is sensitive.

Supporters in Colorado expressed concerns that without proper safeguards, new devices might enable malicious actors to manipulate an individual's thoughts. Lawmakers in California and Minnesota are similarly evaluating protections for neural data.

Modern healthcare and medical research heavily rely on technology and data. As new technologies emerge, they bring expanded challenges for privacy. The recent move by Colorado demonstrates that regulatory frameworks must remain adaptable and flexible, evolving to cover new scenarios that might not have been envisioned just a few years ago. This is particularly relevant for neurodata and neurotechnology.

Link to the Bill

Seamus Larroque

CDPO / CPIM / ISO 27005 Certified

Home

Discover our latest articles

View All Blog Posts
January 19, 2026
Clinical Trial Sponsor
Biotech & Healthtech

Strategic Guide: Clinical Trial Data Protection Compliance in Australia

Are your global data protocols robust enough to withstand an audit by the Office of the Australian Information Commissioner (OAIC)? For international sponsors, Australia represents a premier destination for clinical research, but it also presents a sophisticated "privacy-by-design" regulatory environment. This analysis details the mandatory framework required to align cross-border operations with local statutory obligations and HREC expectations.

August 28, 2025
Clinical Trial Sponsor
Clinical Trials
Consent Forms
Biotech & Healthtech

Scientific Research and the GDPR: Challenges and Opportunities in Secondary Data Use

Turning clinical trial data into tomorrow’s breakthroughs isn’t just science—it’s law. We explore GDPR roadblocks, secondary use challenges, and the UK’s bold new approach.

July 16, 2025
Clinical Trial Sponsor
Clinical Trials

Data Protection Strategies for Phase III Clinical Trials

Phase III clinical trials require strict compliance with privacy and data protection laws across multiple jurisdictions, including GDPR obligations, local authorizations, and ethics committee oversight. The article outlines practical strategies such as the “funnel approach” to harmonize global frameworks, manage cross-border transfers, appoint Data Protection Officers, and ensure proper informed consent documentation. It also emphasizes the need for local representatives, jurisdiction-specific formalities, and standardized templates to maintain compliance and avoid delays in global studies.

FAQs

Our frequently questions

No items found.